A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin(®) (EU) in healthy adult males

BACKGROUND & OBJECTIVES: Trastuzumab (TZ) is a recombinant DNA-derived humanized monoclonal antibody approved for human epidermal growth factor receptor 2 positive early breast cancer, metastatic breast and gastric cancers. For the development of TZ biosimilars, establishing pharmacokinetic equi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lickliter, Jason D., Dadhania, Rakesh Naranbhai, Trivedi, Ravi Kumar, Kumar, S.R. Naveen, Reddy, Pramod Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131799/
https://www.ncbi.nlm.nih.gov/pubmed/35142643
http://dx.doi.org/10.4103/ijmr.IJMR_1119_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131799/
https://www.ncbi.nlm.nih.gov/pubmed/35142643
http://dx.doi.org/10.4103/ijmr.IJMR_1119_18

Ejemplares similares